Key facts for NCD 190.22
- Benefit category
- Diagnostic Laboratory Tests
- Effective date
- 11/25/2002
- Implemented 01/01/2003
- Transmittal
- Transmittal 17
- Versions published
- 1
- Lab edit list
- 1,406 covered ICD-10
- 233 non-covered
TL;DR
NCD 190.22 sets Medicare's national policy for thyroid testing under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. Thyroid function tests are used to define hyper function, euthyroidism, or hypofunction of thyroid disease. Thyroid testing may be reasonable and necessary to: As a laboratory NCD it carries a national ICD-10 edit list: 1,406 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 4 procedure codes.
Item or service described
Thyroid function studies are used to delineate the presence or absence of hormonal abnormalities of the thyroid and pituitary glands. These abnormalities may be either primary or secondary and often but not always accompany clinically defined signs and symptoms indicative of thyroid dysfunction.
Laboratory evaluation of thyroid function has become more scientifically defined. Tests can be done with increased specificity, thereby reducing the number of tests needed to diagnose and follow treatment of most thyroid disease. Measurements of serum sensitive thyroid-stimulating hormone (TSH) levels, complemented by determination of thyroid hormone levels [free thyroxine (fT-4) or total thyroxine (T4) with Triiodothyronine (T3) uptake] are used for diagnosis and follow-up of patients with thyroid disorders.
Additional tests may be necessary to evaluate certain complex diagnostic problems or on hospitalized patients, where many circumstances can skew tests results. When a test for total thyroxine (total T4 or T4 radioimmunoassay) or T3 uptake is performed, calculation of the free thyroxine index (FTI) is useful to correct for abnormal results for either total T4 or T3 uptake due to protein binding effects.
Indications and limitations of coverage
Indications
Thyroid function tests are used to define hyper function, euthyroidism, or hypofunction of thyroid disease. Thyroid testing may be reasonable and necessary to:
• Distinguish between primary and secondary hypothyroidism;
• Confirm or rule out primary hypothyroidism;
• Monitor thyroid hormone levels (for example, patients with goiter, thyroid nodules, or thyroid cancer);
• Monitor drug therapy in patients with primary hypothyroidism;
• Confirm or rule out primary hyperthyroidism; and
• Monitor therapy in patients with hyperthyroidism.
Thyroid function testing may be medically necessary in patients with disease or neoplasm of the thyroid and other endocrine glands. Thyroid function testing may also be medically necessary in patients with metabolic disorders; malnutrition; hyperlipidemia; certain types of anemia; psychosis and non-psychotic personality disorders; unexplained depression; ophthalmologic disorders; various cardiac arrhythmias; disorders of menstruation; skin conditions; myalgias; and a wide array of signs and symptoms, including alterations in consciousness; malaise; hypothermia; symptoms of the nervous and musculoskeletal system; skin and integumentary system; nutrition and metabolism; cardiovascular; and gastrointestinal system.
It may be medically necessary to do follow-up thyroid testing in patients with a personal history of malignant neoplasm of the endocrine system and in patients on long-term thyroid drug therapy.
Limitations
Testing may be covered up to two times a year in clinically stable patients; more frequent testing may be reasonable and necessary for patients whose thyroid therapy has been altered or in whom symptoms or signs of hyperthyroidism or hypothyroidism are noted.
Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).
Text reproduced from the CMS Medicare Coverage Database record for NCD 190.22 version 1. View the original on cms.gov.
Laboratory NCD code lists (October 2026)
Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 1,406 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.
4 procedure codes are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.
| Code | Code set |
|---|---|
| 84436 | CPT (descriptor licensed by AMA) |
| 84439 | CPT (descriptor licensed by AMA) |
| 84443 | CPT (descriptor licensed by AMA) |
| 84479 | CPT (descriptor licensed by AMA) |
What Medicare pays for these tests: 4 of the 4 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $6.47 to $16.80, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.
| Code | CLFS amount | With QW | Pricing |
|---|---|---|---|
| 84436 | $6.87 | — | national payment amount |
| 84439 | $9.02 | — | national payment amount |
| 84443 | $16.80 | $16.80 | national payment amount |
| 84479 | $6.47 | — | national payment amount |
The first 40 of 1,406 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.
| ICD-10-CM | Description | Effective |
|---|---|---|
| A18.81 | Tuberculosis of thyroid gland | 2015-10-01 |
| C56.1 | Malignant neoplasm of right ovary | 2015-10-01 |
| C56.2 | Malignant neoplasm of left ovary | 2015-10-01 |
| C56.3 | Malignant neoplasm of bilateral ovaries | 2021-10-01 |
| C56.9 | Malignant neoplasm of unspecified ovary | 2015-10-01 |
| C73 | Malignant neoplasm of thyroid gland | 2015-10-01 |
| C75.8 | Malignant neoplasm with pluriglandular involvement, unspecified | 2015-10-01 |
| C79.63 | Secondary malignant neoplasm of bilateral ovaries | 2021-10-01 |
| C79.89 | Secondary malignant neoplasm of other specified sites | 2015-10-01 |
| C79.9 | Secondary malignant neoplasm of unspecified site | 2015-10-01 |
| D09.3 | Carcinoma in situ of thyroid and other endocrine glands | 2015-10-01 |
| D09.8 | Carcinoma in situ of other specified sites | 2015-10-01 |
| D27.0 | Benign neoplasm of right ovary | 2015-10-01 |
| D27.1 | Benign neoplasm of left ovary | 2015-10-01 |
| D27.9 | Benign neoplasm of unspecified ovary | 2015-10-01 |
| D34 | Benign neoplasm of thyroid gland | 2015-10-01 |
| D35.2 | Benign neoplasm of pituitary gland | 2015-10-01 |
| D35.3 | Benign neoplasm of craniopharyngeal duct | 2015-10-01 |
| D44.0 | Neoplasm of uncertain behavior of thyroid gland | 2015-10-01 |
| D44.2 | Neoplasm of uncertain behavior of parathyroid gland | 2015-10-01 |
| D44.9 | Neoplasm of uncertain behavior of unspecified endocrine gland | 2015-10-01 |
| D49.7 | Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system | 2015-10-01 |
| D51.0 | Vitamin B12 deficiency anemia due to intrinsic factor deficiency | 2015-10-01 |
| D53.9 | Nutritional anemia, unspecified | 2015-10-01 |
| D59.0 | Drug-induced autoimmune hemolytic anemia | 2015-10-01 |
| D59.10 | Autoimmune hemolytic anemia, unspecified | 2020-10-01 |
| D59.11 | Warm autoimmune hemolytic anemia | 2020-10-01 |
| D59.12 | Cold autoimmune hemolytic anemia | 2020-10-01 |
| D59.13 | Mixed type autoimmune hemolytic anemia | 2020-10-01 |
| D59.19 | Other autoimmune hemolytic anemia | 2020-10-01 |
| D64.89 | Other specified anemias | 2016-10-01 |
| D64.9 | Anemia, unspecified | 2015-10-01 |
| D89.82 | Autoimmune lymphoproliferative syndrome [ALPS] | 2015-10-01 |
| D89.831 | Cytokine release syndrome, grade 1 | 2020-10-01 |
| D89.832 | Cytokine release syndrome, grade 2 | 2020-10-01 |
| D89.833 | Cytokine release syndrome, grade 3 | 2020-10-01 |
| D89.834 | Cytokine release syndrome, grade 4 | 2020-10-01 |
| D89.835 | Cytokine release syndrome, grade 5 | 2020-10-01 |
| D89.839 | Cytokine release syndrome, grade unspecified | 2020-10-01 |
| D89.84 | IgG4-related disease | 2023-10-01 |
233 diagnosis codes deny automatically under this NCD; the first 20 are shown.
| ICD-10-CM | Description |
|---|---|
| R99 | Ill-defined and unknown cause of mortality |
| Z00.00 | Encounter for general adult medical examination without abnormal findings |
| Z00.01 | Encounter for general adult medical examination with abnormal findings |
| Z00.110 | Health examination for newborn under 8 days old |
| Z00.111 | Health examination for newborn 8 to 28 days old |
| Z00.121 | Encounter for routine child health examination with abnormal findings |
| Z00.129 | Encounter for routine child health examination without abnormal findings |
| Z00.5 | Encounter for examination of potential donor of organ and tissue |
| Z00.6 | Encounter for examination for normal comparison and control in clinical research program |
| Z00.70 | Encounter for examination for period of delayed growth in childhood without abnormal findings |
| Z00.71 | Encounter for examination for period of delayed growth in childhood with abnormal findings |
| Z00.8 | Encounter for other general examination |
| Z02.0 | Encounter for examination for admission to educational institution |
| Z02.1 | Encounter for pre-employment examination |
| Z02.2 | Encounter for examination for admission to residential institution |
| Z02.3 | Encounter for examination for recruitment to armed forces |
| Z02.4 | Encounter for examination for driving license |
| Z02.5 | Encounter for examination for participation in sport |
| Z02.6 | Encounter for examination for insurance purposes |
| Z02.71 | Encounter for disability determination |
Changed in October 2026
The October 2026 lab NCD release changed this NCD's ICD-10-CM list: 3 codes added and 1 code removed against January 2026. CMS marked 3 rows of the list as changed in this release. A removed code stops counting for the edit after its term date; where the FY2027 ICD-10-CM update deleted the code, the replacement codes listed below are the ones to report from October 1, 2026.
| ICD-10-CM | FY2027 description | Result |
|---|---|---|
| I49.81 | Brugada syndrome | covered |
| I49.82 | Ventricular bigeminy | covered |
| I49.89 | Other specified cardiac arrhythmias not elsewhere classified | covered |
| ICD-10-CM | Description | Was | Why |
|---|---|---|---|
| I49.8 | Other specified cardiac arrhythmias | covered | deleted from ICD-10-CM; replaced by G90.A, I49.81, I49.82, I49.89 |
Codes on this NCD's list by release: October 2025: 1,620 · January 2026: 1,637 · October 2026: 1,639. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.
Local policies that build on this NCD
2 active Local Coverage Determinations cite NCD 190.22 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.
- Frequency of Laboratory Tests, LCD L35099 · Novitas Solutions, Inc.
- L38968 Thyroid Nodule Molecular Testing · Wellpoint Federal
How MACs bill NCD 190.22
A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 1 current article in the Medicare Coverage Database names NCD 190.22, 1 of them with a covered ICD-10-CM list, from 1 contractor. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.
| Contractor | Articles |
|---|---|
| Wellpoint Federal | A58656 |
A58656: Billing and Coding: Thyroid Nodule Molecular Testing
Billing and Coding, effective 2026-04-01 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record
10 covered ICD-10-CM codes; 4 procedure codes: 0018U, 0026U, 81546, 81599. Local policy: L38968 Thyroid Nodule Molecular Testing. Check a diagnosis for 0018U.
First covered codes: D44.0 Neoplasm of uncertain behavior of thyroid gland; D44.9 Neoplasm of uncertain behavior of unspecified endocrine gland; E01.0 Iodine-deficiency related diffuse (endemic) goiter; E01.1 Iodine-deficiency related multinodular (endemic) goiter; E01.2 Iodine-deficiency related (endemic) goiter, unspecified; E04.0 Nontoxic diffuse goiter; …
Revision history
07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)
07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
For teams evaluating QuickIntell software
Evaluate a coverage-review workflow around NCD 190.22
Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — NCD 190.22
What does NCD 190.22 cover?
Thyroid function tests are used to define hyper function, euthyroidism, or hypofunction of thyroid disease. Thyroid testing may be reasonable and necessary to: The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 190.22 take effect?
The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.
Does a Local Coverage Determination override NCD 190.22?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Which diagnosis codes are covered under NCD 190.22?
The October 2026 laboratory NCD edit list contains 1,406 ICD-10-CM codes that support thyroid testing (for example A18.81 Tuberculosis of thyroid gland; C56.1 Malignant neoplasm of right ovary; C56.2 Malignant neoplasm of left ovary) and 233 codes that deny. The list applies to 84436, 84439, 84443, 84479.
How often does the lab NCD code list for 190.22 change?
CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.
CMS guidance
Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:
- Complying With Documentation Requirements for Lab Services(MLN909221, )What documentation supports a laboratory claim: the order, the medical necessity and the results.
- Clinical Laboratory Fee Schedule(MLN006818, )How the Clinical Laboratory Fee Schedule is set, including data reporting and the payment determination.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- Laboratory NCD ICD-10 code lists, October 2026Version October 2026 · effective 2026-10-01 · file 2026400-Initial-ICD10-NCD-Spreadsheet-20260601-508.xlsxSHA-256 ec4361dc65f63432…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.